# Oritavancin for Staphylococcus Aureus Infections in Opioid Users

> **NCT03761953** · PHASE4 · WITHDRAWN · sponsor: **University of Pennsylvania**

## Conditions studied

- Staphylococcus Aureus Bacteremia
- Staphylococcus Aureus Endocarditis

## Interventions

- **DRUG:** Oritavancin Injection

## Key facts

- **NCT ID:** NCT03761953
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-07-01
- **Primary completion:** 2022-03-24
- **Final completion:** 2022-03-24
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** COVID 19 pandemic
- **Last updated:** 2022-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03761953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03761953, "Oritavancin for Staphylococcus Aureus Infections in Opioid Users". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT03761953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*